EP3076988B1 - Pharmaceutical compositions and methods for the treatment and prevention of metastatic cancer - Google Patents

Pharmaceutical compositions and methods for the treatment and prevention of metastatic cancer Download PDF

Info

Publication number
EP3076988B1
EP3076988B1 EP14824545.9A EP14824545A EP3076988B1 EP 3076988 B1 EP3076988 B1 EP 3076988B1 EP 14824545 A EP14824545 A EP 14824545A EP 3076988 B1 EP3076988 B1 EP 3076988B1
Authority
EP
European Patent Office
Prior art keywords
cancer
peptide
seq
amino acid
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP14824545.9A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3076988A1 (en
Inventor
Yoram Devary
Uziel Sandler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immune System Key Ltd
Original Assignee
Immune System Key Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune System Key Ltd filed Critical Immune System Key Ltd
Publication of EP3076988A1 publication Critical patent/EP3076988A1/en
Application granted granted Critical
Publication of EP3076988B1 publication Critical patent/EP3076988B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • This disclosure generally relates to metastatic cancer therapeutics.
  • cancer is a generic term relating to a large group of diseases that can affect any part of the body.
  • One defining feature of cancer is the rapid creation of abnormal cells that grow beyond their usual boundaries, and which can then invade adjoining parts of the body and spread to other organs in a process referred to as metastasis.
  • Cancer metastasis is the main cause of mortality in cancer and depends on two key processes: cell migration of cancer cells invading into adjacent tissues followed by intravasation into blood/lymphatic vessels and tumor vasculature, which give access to the blood- stream (1).
  • Cancer metastasis is known as a complex, multi-step process that leads to the spread of cancer throughout the body and sometimes requires a therapeutic approach that differs from the approach that was chosen for treating the primary cancer.
  • colorectal carcinoma one of the most common cancers, approximately 50% of colorectal carcinoma patients develop liver metastases at some point during the course of their disease (2). Patients who are candidates for surgical resection of their liver metastases can expect a prolonged survival or even a cure. Unfortunately, only 10% to 25% of patients are candidates for liver resection and in patients with unresectable metastases, chemotherapy is the treatment of choice.
  • Complete response to a treatment in cancer is usually defined as the disappearance of target lesions on imaging.
  • Benoist, S. et al. (2) in more than 25% of cases, macroscopic residual disease was found during surgical exploration at the site of liver metastases that were considered to have disappeared based on imaging.
  • microscopic cancer was observed in the resected specimen from the site of initial liver metastases in 80% of patients.
  • in situ recurrence was observed in 74% of cases after 1 year.
  • T101 A peptide termed " T101" that is encoded by a cDNA unique for the human thymus was identified. This peptide was implicated, inter alia, for the treatment of cancer via its role as a stimulator of the immune system ( WO 2006/046239 , 3). WO 2006/046239 demonstrates that T101 is able to stimulate the immune system and to reduce tumor size, suggesting that the peptide affects the proliferation of cancer cells. Treatment of cancer by using T101 was also suggested in WO 2007/122622 (4), which demonstrates, inter alia, the effect of T101 on the development of various types of tumors. The peptide T101 was also described in WO 2007/091240 (5), relating to treatment of immunological diseases and WO 2008/075349 (6), relating to treating or preventing a disease involving a cell having T1/ST2 receptor.
  • NEROFE Tumor-Cells Apoptosis Factor
  • WO 2007/122622 discloses a method for preventing or treating cancer in a subject in need, comprising administering to the subject a therapeutic amount of a thymus polypeptide or pharmaceutically active fragment thereof.
  • a pharmaceutical composition comprising an isolated peptide consisting of the amino acid sequence of SEQ ID NO: 4 or of any functional fragments of the isolated peptide, wherein said functional fragments have at least 70% identity to SEQ ID NO: 4, for use in a method of preventing or treating cancer metastasis, wherein said cancer is a metastatic cancer.
  • composition comprising an isolated peptide consisting of the amino acid sequence of SEQ ID NO: 4 or of any functional fragments of the isolated peptide, wherein said functional fragments have at least 70% identity to SEQ ID NO: 4, for use in a method of reducing cancer cell motility in a cancer patient.
  • composition comprising an isolated peptide consisting of the amino acid sequence of SEQ ID NO: 4 or of any functional fragments of the isolated peptide, wherein said functional fragments have at least 70% identity to SEQ ID NO: 4, for use in a method of preventing or inhibiting angiogenesis in a cancer patient.
  • composition comprising an isolated peptide comprising the amino acid sequence of SEQ ID NO: 3 or any functional fragments or derivatives of the isolated peptide for use in a method of preventing or treating cancer metastasis.
  • composition comprising an isolated peptide comprising the amino acid sequence of SEQ ID NO: 3 or any functional fragments or derivatives of the isolated peptide for use in a method of reducing cancer cell motility, preventing or inhibiting angiogenesis in a cancer patient or decreasing the level of vascular endothelial growth factor (VEGF) in a cancer patient.
  • VEGF vascular endothelial growth factor
  • Also disclosed is a method of preventing or treating cancer metastasis comprising administering to a cancer patient in need thereof a pharmaceutical composition comprising a therapeutically effective amount of an isolated peptide comprising the amino acid sequence of SEQ ID NO: 3 or any functional fragments or derivatives of the isolated peptide.
  • the isolated peptide as herein defined comprises the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2 or any functional fragments or derivatives of the isolated peptide.
  • the isolated peptide according to the invention consists of the amino acid sequence of SEQ ID NO: 3.
  • the isolated peptide as herein defined comprises a modified amino acid sequence of SEQ ID NO: 3, in which one or more amino acid residues is replaced by conservative substitution without significantly affecting the biological characteristics of the modified peptide as compared to the unmodified peptide having the amino acid sequence of SEQ ID NO: 3.
  • the isolated peptide as herein defined comprises a modified amino acid sequence of SEQ ID NO: 3, in which one or more amino acid residues is replaced by the corresponding D-amino acid residue.
  • the isolated peptide according to the invention comprises the amino acid sequence of SEQ ID NO: 4.
  • the isolated peptide as herein defined consists of the amino acid sequence of SEQ ID NO: 4.
  • the present invention relates to a cancer that is a metastatic cancer.
  • the metastatic cancer is selected from the group consisting of pancreatic cancer, colon cancer, colorectal cancer, colon adenocarcinoma, rectal adenocarcinoma, breast cancer, skin cancer, lung cancer, non small cell lung carcinoma, renal cancer, multiple myeloma, thyroid cancer, prostate cancer, adenocarcinoma, head and neck cancer, gastrointestinal cancer, stomach cancer, cancer of the small intestine, spindle cell neoplasm, hepatic carcinoma, liver cancer and malignancies of the female genital tract.
  • the pharmaceutical composition for use according to the invention is adapted for administration with at least one additional anti-cancer therapy.
  • the method of preventing or treating cancer metastasis according to the invention further comprises administering to said cancer patient at least one additional anti-cancer therapy.
  • the at least one additional cancer therapy as herein defined is selected from the group consisting of an anti-angiogenic agent, a cytotoxic agent, a chemotherapeutic agent, hormonal therapy, radiation therapy and immunotherapy.
  • compositions for use and methods according to the invention are where the administration is by a route selected from the group consisting of intravenous, intraperitoneal, intramuscular, subcutaneous, transcutaneous, topical, intraarticular, subconjunctival, oral, intranasal and intraocular.
  • the present invention is based on the observation that a peptide having the amino acid sequence of Trp Trp Thr Phe Phe Leu Pro Ser Thr Leu Trp Glu Arg Lys in which all of the amino acid residues are at their D configuration, termed herein "Nerofe", decreased the secretion by cancer cells of proteins that are known to be associated with cancer metastasis (i.e. tissue plasminogen activator (TPA) and soluble ST2 (sST2)). This peptide was demonstrated to directly inhibit the migration of cancer cells in vitro. In addition the peptide was shown to decrease the serum level of vascular endothelial growth factor (VEGF) in cancer patients.
  • TPA tissue plasminogen activator
  • sST2 soluble ST2
  • the present invention Based on the decreased secretion of TPA and sST2 by cancer cells upon exposure to the Nerofe peptide, the direct effect of the peptide on the migration ability of cancer cells in vitro, and based on the effect of the Nerofe peptide on the serum levels of VEGF observed in cancer patients, the present invention provides methods and uses of the Nerofe peptide in the inhibition of cancer metastasis.
  • composition comprising an isolated peptide comprising the amino acid sequence of SEQ ID NO: 3, or any functional fragments or derivatives of the isolated peptide, for use in a method of preventing or treating cancer metastasis is disclosed.
  • peptide refers to a molecular chain of amino acid residues, which, if required, can be modified at each one of its amino acid residues, for example by manosylation, glycosylation, amidation (for example C-terminal amides), carboxylation or phosphorylation.
  • the peptide may be obtained synthetically, through genetic engineering methods, expression in a host cell, or through any other suitable means. Methods for producing peptides are well known in the art.
  • isolated refers to molecules, such as amino acid sequences or peptides that are removed from their natural environment, isolated or separated.
  • amino acid refers to naturally occurring and synthetic amino acid residues, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids.
  • Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, ⁇ -carboxyglutamate, and O-phosphoserine.
  • amino acid also encompasses D-amino acids, which are mirror images of L-amino acids, where the chirality at carbon alpha has been inverted. D-amino acids are highly resistant to protease mediated degradation and have a low immunogenic response.
  • amino acid sequence or "peptide sequence” also relate to the order in which amino acid residues, connected by peptide bonds, lie in the chain in peptides and proteins.
  • the sequence is generally reported from the N-terminal end containing free amino group to the C-terminal end containing free carboxyl group.
  • the peptide termed herein "Nerofe” having the sequence of Trp Trp Thr Phe Phe Leu Pro Ser Thr Leu Trp Glu Arg Lys in which all of the amino acid residues are at their D configuration (denoted by SEQ ID NO: 4) was shown to decrease the secretion of TPA and sST2 by cancer cells and to directly inhibit the migration of cancer cells, suggesting its potential in inhibition of cancer metastasis.
  • the peptide having the amino acid sequence of Trp Trp Thr Phe Phe Leu Pro Ser Thr Leu Trp Glu Arg Lys, in which all of the amino acid residues are L amino acid residues (denoted herein by SEQ ID NO: 3), is a C-terminal fragment of the peptide termed "full T101 peptide" that was described in WO 2006/046239 (3).
  • the full T101 peptide is a 84 amino acids long sequence, denoted herein by SEQ ID NO: 1. Deletion of its N-terminal 33 amino acids signal peptide yields a peptide fragment denoted herein by SEQ ID NO: 2 and termed "T101 peptide". The T101 peptide is 51 amino acids long.
  • the amino acid sequences of SEQ ID NO: 1 and SEQ ID NO: 2, as well as of SEQ ID NO: 3 and SEQ ID NO: 4, are detailed in Table 1 below.
  • Table 1 Amino acid sequences of peptides SEQ ID NO. Sequence Description 1 Full length thymus peptide, also termed " full T101 peptide " .
  • the isolated peptide employed in the invention is an isolated peptide consisting of the amino acid sequence of SEQ ID NO: 4 or of any functional fragments of the isolated peptide, wherein said functional fragments have at least 70% identity to SEQ ID NO: 4, for use in a method of preventing or treating cancer metastasis, wherein said cancer is a metastatic cancer.
  • full T101 peptide an isolated peptide comprising at least a contiguous C-terminal fragment of the peptide termed herein "full T101 peptide", for example, but not limited to, the amino acid sequence denoted by SEQ ID NO: 3, which is the C-terminal 14 amino acid residues fragment of the full T101 peptide.
  • the isolated peptide comprises a contiguous C-terminal fragment of the full T101 peptide including at least 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83 or 84 amino acid residues from the C-terminus of the full T101 peptide (denoted by SEQ ID NO: 1).
  • isolated peptide relates to an isolated peptide comprising the amino acid sequence denoted by SEQ ID NO: 3, or any functional fragments and derivatives of the isolated peptide.
  • the isolated peptide is the full T101 peptide as defined below (having SEQ ID NO: 1) or any functional fragments and derivatives of the isolated peptide.
  • the isolated peptide is the thymus peptide T101 devoid of its N-terminal 33 amino acids (having SEQ ID NO: 2) or any functional fragments and derivatives of the isolated peptide.
  • the isolated peptide of the disclosure includes the peptide denoted by SEQ ID NO: 3 or SEQ ID NO 4, but may also include additional amino acid residues at the N-terminus or at the C-terminus of the peptide denoted by SEQ ID NO: 3 or SEQ ID NO: 4, for example, but not limited to, the isolated peptide of the disclosure may comprise the sequences denoted by SEQ ID NO: 1 and SEQ ID NO: 2, as detailed below.
  • the pharmaceutical composition for use relates to an isolated peptide comprising the amino acid sequence Trp Trp Thr Phe Phe Leu Pro Ser Thr Leu Trp Glu Arg Lys as denoted by SEQ ID NO: 3, or any functional fragments or derivatives of said isolated peptide.
  • composition for use is an isolated peptide comprising the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2 or any functional fragments or derivatives of the isolated peptide.
  • composition for use is an isolated peptide consisting of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2 or any functional fragments or derivatives of the isolated peptide.
  • composition for use is an isolated peptide consisting of the amino acid sequence of SEQ ID NO: 3.
  • Derivatives and modified peptides of the isolated peptides as herein defined are also encompassed by the present invention.
  • the terms "modified”, “derivatives” or “derivatives of the isolated peptide” is meant to include peptides, which differ in one or more amino acids in the overall sequence, namely, which have deletions, substitutions (e.g. replacement of at least one amino acid by another amino acid by conservative substitution), inversions or additions. This term also encompasses the replacement of at least one amino acid residue in the overall sequence by its respective D amino acid residue.
  • the peptide Nerofe (denoted by SEQ ID NO: 4) has the amino acid sequence of SEQ ID NO: 3, in which all the amino acid residues have been replaced by their corresponding D amino acid.
  • Amino acid substitutions are the result of replacing one amino acid with another amino acid having similar structural and/or chemical properties, i.e., conservative amino acid replacements.
  • Amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved. For example, each of the following eight groups contains amino acids that are conservative substitutions for one another:
  • Fragments of the isolated peptide of SEQ ID NO: 4 are also included in the present invention.
  • the term “fragment” refers to any peptide which is at least one amino acid shorter than the isolated peptide in accordance with the invention, obtained by deletion of at least one amino acid residue from the peptide in accordance with the invention.
  • a fragment of an isolated peptide comprising the full T101 peptide (denoted by SEQ ID NO: 1) and may be a fragment of at least about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83 or 84 amino acid residues from the C-terminus of the full T101 peptide.
  • modified peptides of the disclosed isolated peptide comprise a modified amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4, in which one or more amino acid residues is replaced by conservative substitution without significantly affecting the biological characteristics of the modified peptide compared to the unmodified peptide having the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4, respectively.
  • the modified amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4 have at least 70%, preferably 80%, more preferably 90%, in particular 100% identity to the corresponding sequences of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4, respectively.
  • the peptide derivatives of the disclosure also encompass any fusion protein or conjugate that comprises the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 4 as well as any isolated peptide as herein defined that is coupled through at least one of its residues to an additional agent (for example a stabilization agent, an anti-angiogenic agent, a cytotoxic agent, etc.).
  • an additional agent for example a stabilization agent, an anti-angiogenic agent, a cytotoxic agent, etc.
  • a modified fragment may be a peptide that includes a contiguous sequence of at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75 or at least 80 amino acid residues from the C-terminus of the full T101 peptide that has a degree of identity of at least 70%, preferably at least 80%, more preferably at least 90% and particularly at least 100% to a corresponding sequence of at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75 or at least 80 included in the full T101 peptide.
  • biological characteristics when referring to the isolated peptide of the invention encompasses inhibition of cancer cell migration, reduction of the secreted level of tissue Type Plasminogen Activator (TPA), reduction of the secreted level of soluble ST2 in cancer cells and reduction of the secreted levels of VEGF.
  • TPA tissue Type Plasminogen Activator
  • one or more assays can be carried out, such as for example an in vitro, in vivo or a clinical experiment in which a modified peptide is compared to the corresponding unmodified one that is assayed in parallel; or an experiment in which the modified peptide is assayed to examine whether it has a biological effect similar to that of the unmodified peptide as known from separately conducted experiment.
  • Such an experiment may be carried out, for example, in manner described in the Examples below.
  • functional fragments, derivatives or modified peptides wherein said functional fragments, derivative or modified peptides have an amino acid sequence that is at least 70%, preferably at least 80%, more preferably at least 90% and particularly at least 95% identical to the amino acid sequence of the unmodified isolated peptide are disclosed, namely to one of the amino acid sequences denoted by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 4.
  • the pharmaceutical composition for use is an isolated peptide comprising a modified amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 4, in which one or more amino acid residues is replaced by conservative substitution without significantly affecting the biological characteristics of the modified peptide as compared to the unmodified peptide having the amino acid sequence of SEQ ID NO: 3 or respectively SEQ ID NO: 4.
  • the pharmaceutical composition for use is an isolated peptide comprising a modified amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 4, in which one or more amino acid residues is replaced by conservative substitution without significantly affecting the biological characteristics of the modified peptide as compared to the unmodified peptide having the amino acid sequence of SEQ ID NO: 3 or respectively SEQ ID NO: 4, wherein said modified amino acid sequence is at least 70%, preferably at least 80%, more preferably at least 90% and particularly at least 95% identical to the amino acid sequence of the unmodified peptide having the amino acid sequence of SEQ ID NO: 3 or respectively SEQ ID NO: 4.
  • composition for use is an isolated peptide comprising a modified amino acid sequence of SEQ ID NO: 3, in which one or more amino acid residues is replaced by the corresponding D-amino acid residue.
  • composition for use is an isolated peptide comprising the amino acid sequence of SEQ ID NO: 4.
  • the pharmaceutical composition for use according to the invention is an isolated peptide consisting of the amino acid sequence of SEQ ID NO: 4.
  • Neofe the peptide termed herein "Nerofe” was shown to directly inhibit cell motility or migration in pancreatic cancer cells and breast cancer cells.
  • the ability of cancer cells to migrate from their original site to a different location in the body is one of the basic steps in cancer metastasis.
  • cancer metastasis refers to the process of spreading or migration of a cancer from the location where it first developed to another location or site in the body.
  • the term cancer metastasis also relates to a tumor formed by metastatic cancer cells at a location which is different from the original site of the metastatic cancer cells.
  • a tumor formed by metastatic cancer cells is also called a metastatic tumor.
  • Cancer cell metastasis usually involves the following steps: local invasion of cancer cells to nearby normal tissue; intravasation, whereby cancer cells invade and move through the walls of nearby lymph vessels or blood vessels; circulation of cancer cells through the lymphatic system and the bloodstream to other parts of the body; arrest and extravasation, whereby cancer cells arrest in small blood vessels at a distant location and then invade the walls of the capillaries and migrate into the surrounding tissue (extravasation); proliferation of cancer cells at the distant location to form small tumors known as micrometastases; and angiogenesis, the stimulation of growth of new blood vessels by micrometastases to obtain a blood supply.
  • the most common sites of cancer metastasis are bone, liver, lung and brain.
  • the present invention encompasses any cancer disease that may form metastasis or secondary growth.
  • Predicting which types of cancer will ultimately develop metastases may be performed by a skilled physician (e.g. a physician specializing in oncology).
  • a prediction of the metastatic potential of the cancer is based, inter alia, on the overall stage of cancer, including the size, depth, and whether or not lymph nodes are involved. Other indicators may be tumor grade and genetic and protein tests.
  • Identifying or diagnosing cancer metastasis may be performed by a skilled physician for example by following the appearance of symptoms such as bone pain, persistent cough, and headache which can be signs of metastatic cancer.
  • metastatic cancer may be detected by routine scans, such as blood tests, imaging (e.g. X-rays, positron emission tomography and computed tomography (PET/CT), magnetic resonance imaging (MRI), bone scan, MRI and CT) and a biopsy which is usually done to confirm a suspicious diagnosis.
  • imaging e.g. X-rays, positron emission tomography and computed tomography (PET/CT), magnetic resonance imaging (MRI), bone scan, MRI and CT
  • MRI magnetic resonance imaging
  • the invention relates to a cancer that is classified as a "metastatic cancer", namely any cancer type that is known in the art as having a metastatic potential.
  • the cancer encompassed by the present invention is a metastatic cancer.
  • the metastatic cancer as herein defined is selected from the group consisting of pancreatic cancer, colon cancer, colorectal cancer, colon adenocarcinoma, rectal adenocarcinoma, breast cancer, skin cancer, lung cancer, non small cell lung carcinoma, renal cancer, multiple myeloma, thyroid cancer, prostate cancer, adenocarcinoma, head and neck cancer, gastrointestinal cancer, stomach cancer, cancer of the small intestine, spindle cell neoplasm, hepatic carcinoma, liver cancer and malignancies of the female genital tract.
  • the serum level of VEGF was decreased by about 30-40% when cancer patients were administered with the peptide Nerofe, at a dose of 24 mg/m 2 or 48 mg/m 2 (given in Body Surface Area units and translates to about 0.64 or about 1.28 mg/kg body weight, respectively).
  • the decrease in the serum level of VEGF was particularly significant for cancer patients having small intestine and rectal adenocarcinoma cancers.
  • vascular endothelial growth factor is a signal protein produced by cells that stimulate vasculogenesis and angiogenesis.
  • VEGF's normal function is to create new blood vessels during embryonic development, new blood vessels after injury, muscle following exercise, and new vessels to bypass blocked vessels. It is known that over-expression of VEGF may contribute to disease. Since solid cancers cannot grow beyond a limited size without an adequate blood supply, cancers that can express VEGF are able to grow and metastasize.
  • the observed decrease in the serum level of VEGF as a result of administering the peptide Nerofe to cancer patients is a clear anti-angiogenic effect of the Nerofe peptide.
  • the present invention provides a pharmaceutical composition comprising an isolated peptide as herein defined for use in a method of preventing or inhibiting angiogenesis in a cancer patient.
  • the angiogenesis is tumor associated angiogenesis.
  • the angiogenesis is associated with VEGF.
  • a pharmaceutical composition comprising an isolated peptide comprising the amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 4 or any functional fragments or derivatives of the isolated peptide for use in a method of preventing or inhibiting angiogenesis is disclosed.
  • composition comprising an isolated peptide consisting of the amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 4 or any functional fragments or derivatives of the isolated peptide for use in a method of preventing or inhibiting angiogenesis is disclosed.
  • angiogenesis refers to the process by which new blood vessels are formed and is involved in various physiological as well as pathological processes including wound repair, reproduction, response to ischemia, arthritis, psoriasis, retinopathies, solid tumor growth and metastatic tumor spread.
  • Angiogenesis is a highly-controlled process that is dependent on the intricate balance of both promoting and inhibiting factors.
  • preventing or inhibiting angiogenesis any restriction, retardation, reduction, decrease or diminishing of angiogenesis by at least about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or about 100%.
  • preventing or inhibiting angiogenesis it is also meant the prevention or inhibition of any new blood vessel formation, including but not limited to inhibition of vasculogenesis (the de novo formation of endothelial cells from mesoderm cell precursors).
  • angiogenesis may be monitored by any method known in the art, for example by imaging or by monitoring physiological markers associated with angiogenesis (for example vascular endothelial growth factor).
  • physiological markers associated with angiogenesis for example vascular endothelial growth factor.
  • vascular endothelial growth factor is a mitogenic factor that stimulates pro-angiogenic properties, including endothelial cell migration, tube formation and proliferation.
  • VEGF vascular endothelial growth factor
  • the observed decrease in the serum level of VEGF as a result of administering the peptide Nerofe to cancer patients indicates an anti-angiogenic effect of the Nerofe peptide.
  • composition comprising an isolated peptide as herein defined for use in a method of decreasing the level of VEGF in a cancer patient is disclosed.
  • Measuring the level of VEGF in a cancer patient administered with the isolated peptide as herein defined may be performed using any method known in the art, for example by obtaining biological samples (e.g. blood) from the patient before the beginning of the treatment with the isolated peptide as herein defined and at various time points during the treatment and thereafter.
  • biological samples e.g. blood
  • the levels of VEGF in these biological samples may be determined following procedures well known in the art.
  • a decrease in the level of VEGF is observed when the serum levels of VEGF in biological sample(s) obtained from a cancer patient after the beginning of the treatment with the isolated peptide as herein defined are lower than the serum levels of VEGF in biological sample(s) obtained from a cancer patient before the treatment was started.
  • any decrease in the serum level of VEGF in the blood of a cancer patient administered with the isolated peptide as herein defined is encompassed by the present invention.
  • the decrease in the serum level of VEGF may be of at least about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or about 100%.
  • composition comprising an isolated peptide comprising the amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 4 or any functional fragments or derivatives of the isolated peptide for use in a method of decreasing the level of VEGF is disclosed.
  • composition comprising an isolated peptide consisting of the amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 4 or any functional fragments or derivatives of the isolated peptide for use in a method of decreasing the level of VEGF.
  • metastatic cancer which is associated with overexpression of VEGF.
  • the metastatic cancer as herein defined may be but is not limited to pancreatic cancer, small intestine cancer, rectal adenocarcinoma, colon cancer, colorectal cancer, spindle cell neoplasm, non small cell lung carcinoma, hepatic carcinoma and rectal adenocarcinoma.
  • the invention relates to a metastatic cancer which is pancreatic cancer, breast cancer, small intestine cancer or rectal adenocarcinoma.
  • pancreatic cancer refers to uncontrolled growth of the cells that make up the pancreas (a glandular organ located behind the stomach). These cancer cells have the ability to invade or spread to other parts of the body. There are a number of different types of pancreatic cancer, but pancreatic adenocarcinoma accounts for about 85% of cases.
  • breast cancer refers to a cancer that forms in tissues of the breast.
  • the most common type of breast cancer is ductal carcinoma, which begins in the lining of the milk ducts.
  • Another type of breast cancer is lobular carcinoma, which begins in the lobules (milk glands) of the breast.
  • Invasive breast cancer is breast cancer that has spread from where it began in the breast ducts or lobules to surrounding normal tissue.
  • small intestine cancer is a rare disease in which malignant cancer cells form in the tissues of the small intestine.
  • rectal adenocarcinoma relates to a disease in which cancer cells form in the tissues of the rectum.
  • Adenocarcinomas comprise the vast majority (98%) of colon and rectal cancers and more rare rectal cancers include lymphoma (1.3%), carcinoid (0.4%), and sarcoma (0.3%).
  • compositions comprising an isolated peptide comprising the amino acid sequence of SEQ ID NO: 4, or any functional fragments or derivatives of the isolated peptide, for use in a method of preventing or treating pancreatic cancer or breast cancer metastasis is disclosed.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising an isolated peptide consisting of the amino acid sequence of SEQ ID NO: 4, or any functional fragments or derivatives of the isolated peptide, for use in a method of preventing or treating pancreatic cancer metastasis.
  • the intended use of the methods and pharmaceutical compositions for use in accordance with the invention is preventing or treating cancer metastasis in a subject in need thereof.
  • the methods and pharmaceutical compositions for use in accordance with the present invention are intended to prevent the formation of cancer metastases in a patient diagnosed as having cancer.
  • the pharmaceutical composition of the invention may be administered per se or in combination with other anti-cancer agents as a "preventive" or adjuvant plan, to be administered in addition to the main therapy that is administered to an individual diagnosed with cancer.
  • the main therapy may be for example surgery and/or chemotherapy.
  • adjuvant therapy refers to a treatment that is given in addition to the primary, main or initial treatment.
  • adjuvant therapy administered to a cancer patient currently known are chemotherapy, hormonal therapy, biological therapy, radiation therapy, or a combination thereof depending on the type of cancer.
  • adjuvant therapy is designed to lower the risk of future metastases, but is not a guarantee against recurrence.
  • the pharmaceutical composition for use according to the invention is wherein said pharmaceutical composition is adapted for administration with at least one additional anti-cancer therapy.
  • the invention provides methods and pharmaceutical composition for use in the treatment of a subject diagnosed with cancer (a cancer patient) optionally in combination with the primary, main or initial treatment, in order to prevent the development of cancer metastases.
  • the administration of the pharmaceutical composition may be performed before, simultaneously with of after the administration of the at least one additional anti-cancer therapy
  • At least one additional anti-cancer therapy refers to any anti-cancer therapy known in the art, for example, but is not limited to, an anti-angiogenic agent, a cytotoxic agent, a chemotherapeutic agent (for example alkylating agents, anti-metabolites, topoisomerase inhibitors and cytotoxic antibiotics), hormonal therapy (for example Tamoxifen for the treatment of breast cancer), radiation therapy and immunotherapy (for example cell-based therapies, antibody therapies or cytokine therapy).
  • an anti-angiogenic agent for example, but is not limited to, an anti-angiogenic agent, a cytotoxic agent, a chemotherapeutic agent (for example alkylating agents, anti-metabolites, topoisomerase inhibitors and cytotoxic antibiotics), hormonal therapy (for example Tamoxifen for the treatment of breast cancer), radiation therapy and immunotherapy (for example cell-based therapies, antibody therapies or cytokine therapy).
  • a chemotherapeutic agent for example alkylating agents, anti-metabolites, topoi
  • anti-angiogenic agent refers to a substance that inhibits the growth of new blood vessels (angiogenesis).
  • agents that inhibit angiogenesis are agents that reduce the production of pro-angiogenic factors and inhibitors of the VEGF pathway, to name but few.
  • Inhibitors of the VEGF pathway may be for example tyrosine kinase inhibitors and antibodies directed against VEGF or VEGFR, such as Bevacizumab (Avastin) that binds to VEGF and inhibits it from binding to VEGF receptors.
  • said at least one additional cancer therapy is selected from the group consisting of an anti-angiogenic agent, a cytotoxic agent, a chemotherapeutic agent, hormonal therapy, radiation therapy and immunotherapy.
  • preventing means any restriction, retardation, reduction, decrease, hindering, inhibiting, impeding or suppressing of the formation of cancer metastases in an individual diagnosed with cancer (a cancer patient), where the cancer may optionally be diagnosed as a metastatic cancer.
  • preventing as herein defined means any restriction, retardation, reduction, decrease, hindering, inhibiting, impeding or suppressing of the formation of cancer metastases in an individual diagnosed with cancer by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or about 100%.
  • the invention also provides a pharmaceutical composition as herein defined for use in a method of treating cancer metastasis.
  • the method in accordance with the invention may also be useful for the "treatment of cancer metastasis", which is herein defined as the prevention of continued or further spread of metastatic cancer cells after cancer metastasis was diagnosed in a cancer patient.
  • cancer patient or “cancer patient in need thereof” as herein defined thus refers to warm-blooded animals, in particular humans that were diagnosed as having cancer inter alia metastatic cancer.
  • treat means to prevent, inhibit, arrest or alleviate the patient's disease or condition.
  • the level of hindering, inhibiting, impeding or suppressing of the formation of cancer metastases may be evaluated experimentally by performing suitable assays in the presence of the isolated peptide of the invention, as known in the art.
  • a clinical evaluation of the level of hindering, inhibiting, impeding or suppressing of the formation of cancer metastases may be performed by a skilled physician, for example as described above.
  • the pharmaceutical composition or the pharmaceutical composition for use in accordance with the invention can be administered and dosed in accordance with good medical practice, for example systemically by parenteral, intravenous, intraperitoneal or intramuscular injection.
  • the pharmaceutical composition can be introduced to a site by any suitable route including intravenous, subcutaneous, transcutaneous, topical, intramuscular, intraarticular, subconjunctival, or mucosal, e.g. oral, intranasal, or intraocular administration.
  • the administration according to the invention is by a route selected from the group consisting of intravenous, intraperitoneal, intramuscular, subcutaneous, transcutaneous, topical, intraarticular, subconjunctival, oral, intranasal and intraocular.
  • composition comprising an isolated peptide comprising the amino acid sequence of SEQ ID NO: 3 or any functional fragments or derivatives of the isolated peptide for use in a method of reducing cancer cell motility is disclosed.
  • the pharmaceutical composition as herein defined is for use in a method of reducing cancer cell motility in a cancer patient diagnosed with cancer with a metastatic potential.
  • reducing cancer cell motility it is meant any partial or complete inhibition, attenuation or decrease in the ability of cancer cells to migrate from their location. Cancer cell migration may be monitored by any method known in the art, for example by the cell migration assay exemplified below.
  • composition or “pharmaceutical composition” as herein defined generally comprises an active agent being the isolated peptide in accordance with the invention and at least one of a buffering agent, an agent which adjusts the osmolarity thereof, and optionally, at least one pharmaceutically acceptable carriers, excipients and/or additives as known in the art.
  • compositions according to the invention may be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutically acceptable carrier(s), excipient(s) or additive(s).
  • pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents as well known in the art.
  • Each carrier should be both pharmaceutically and physiologically acceptable in the sense of being compatible with the other ingredients and not injurious to the patient.
  • the pharmaceutically acceptable carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
  • a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
  • Supplementary or additive active ingredients for example additional anti-cancer agents, can also be incorporated into the pharmaceutical composition of the invention.
  • formulations may also include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavoring agents.
  • compositions and pharmaceutical compositions for use in accordance with the invention further comprises at least one pharmaceutically acceptable carrier, excipient and/or additive.
  • a method of preventing or treating cancer metastasis comprising administering to a cancer patient in need thereof a pharmaceutical composition comprising a therapeutically effective amount of an isolated peptide comprising the amino acid sequence of SEQ ID NO.3 or any functional fragments or derivatives of the isolated peptide is disclosed.
  • the method of preventing or treating cancer metastasis according to the disclosure is wherein said isolated peptide as herein defined comprises the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2 or any functional fragments or derivatives of the isolated peptide.
  • the method of preventing or treating cancer metastasis according to the disclosure is wherein said isolated peptide consists of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2 or any functional fragments or derivatives of the isolated peptide.
  • the method of preventing or treating cancer metastasis according to the disclosure is wherein said isolated peptide consists of the amino acid sequence of SEQ ID NO: 3.
  • the method of preventing or treating cancer metastasis is wherein said isolated peptide comprises a modified amino acid sequence of SEQ ID NO: 3, or SEQ ID NO: 4, in which one or more amino acid residues is replaced by conservative substitution without significantly affecting the biological characteristics of the modified peptide as compared to the unmodified peptide having the amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 4, respectively.
  • the method of preventing or treating cancer metastasis according to the disclosure is wherein said isolated peptide comprises a modified amino acid sequence of SEQ ID NO: 3, in which one or more amino acid residues is replaced by the corresponding D-amino acid residue.
  • the method of preventing or treating cancer metastasis is wherein said isolated peptide comprises the amino acid sequence of SEQ ID NO: 4.
  • the present invention provides a method of preventing or treating cancer metastasis comprising administering to a cancer patient in need thereof a pharmaceutical composition comprising a therapeutically effective amount of an isolated peptide consisting of the amino acid sequence of SEQ ID NO: 4.
  • the method of preventing or treating cancer metastasis according to the invention is wherein said method further comprises administering to said cancer patient at least one additional anti-cancer therapy as herein defined.
  • Also disclosed is a method of reducing cancer cell motility comprising administering to a cancer patient diagnosed with cancer with a metastatic potential a pharmaceutical composition comprising a therapeutically effective amount of an isolated peptide comprising the amino acid sequence of SEQ ID NO. 3 or any functional fragments or derivatives of the isolated peptide.
  • a method of preventing or inhibiting angiogenesis in a cancer patient comprising administering to a cancer patient in need thereof a pharmaceutical composition comprising a therapeutically effective amount of an isolated peptide comprising the amino acid sequence of SEQ ID NO: 3 or any functional fragments or derivatives of the isolated peptide.
  • a method of decreasing the level of VEGF in the serum of a cancer patient in need thereof comprising administering to said cancer patient a pharmaceutical composition comprising a therapeutically effective amount of an isolated peptide comprising the amino acid sequence of SEQ ID NO: 3 or any functional fragments or derivatives of the isolated peptide is disclosed.
  • the method of reducing cancer cell motility, the method of preventing or inhibiting angiogenesis or the method of decreasing the level of VEGF in the serum of a cancer patient in need thereof in accordance with the present disclosure is wherein said pharmaceutical composition comprises a therapeutically effective amount of an isolated peptide comprising the amino acid sequence of SEQ ID NO: 4.
  • the method of reducing cancer cell motility, the method of preventing or inhibiting angiogenesis or the method of decreasing the level of VEGF in the serum of a cancer patient in need thereof in accordance with the present disclosure is wherein said pharmaceutical composition comprises a therapeutically effective amount of an isolated peptide consisting of the amino acid sequence of SEQ ID NO: 4.
  • the "therapeutically effective amount” (or amounts) of the isolated peptide in accordance with the invention for purposes herein defined is determined by such considerations as are known in the art in order to treat, prevent, inhibit, arrest or alleviate cancer metastasis.
  • the isolated peptide or the pharmaceutical composition comprising thereof in accordance with the invention may be administered to a patient in need thereof in a single of multiple doses at a therapeutically effective amount.
  • the dosing regimen and dosing schedule of administration of the isolated peptide or the pharmaceutical composition comprising same as herein defined may be determined by a skilled person based on considerations known in the art, for example but not limited to, following the clinical assay summarized in Table 3 below.
  • the methods of treatment and the pharmaceutical compositions for use as herein defined are intended to inhibit, hinder or slow-down the progression of cancer metastasis.
  • Monitoring the therapeutic effect of the isolated peptide as herein defined may be regularly performed by a skilled physician, for example by an assessment of all tumors and following their size and metastasis or by following the symptoms of cancer metastasis in a cancer patient as known in the art, for example as described above.
  • determining the responsiveness of a cancer patient to a treatment comprising administering a pharmaceutical composition for use as defined herein may be performed by following specific markers of cancer metastasis, for example but not limited to at least one of the level of secreted soluble ST2, TPA or VEGF from a biological sample containing cells obtained from the cancer patient before being treated by the methods and pharmaceutical compositions for use as herein defined and at a regular manner (for example once weekly, once in every two weeks, once a month) after being treated.
  • specific markers of cancer metastasis for example but not limited to at least one of the level of secreted soluble ST2, TPA or VEGF from a biological sample containing cells obtained from the cancer patient before being treated by the methods and pharmaceutical compositions for use as herein defined and at a regular manner (for example once weekly, once in every two weeks, once a month) after being treated.
  • Biological sample is used in its broadest sense. Biological samples may be obtained from animals (including humans) and encompass fluids (for example blood), solids and tissues.
  • the present invention provides use of an isolated peptide or any functional fragments or derivatives of the isolated peptide as herein defined in the preparation of a pharmaceutical composition for preventing or treating cancer metastasis.
  • an isolated peptide comprising the amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 4 or any functional fragments or derivatives of the isolated peptide in the preparation of a pharmaceutical composition for preventing or treating cancer metastasis comprising administering to a cancer patient in need thereof is disclosed.
  • the present invention further provides the use of an isolated peptide or any functional fragments or derivatives of the isolated peptide as herein defined in the preparation of a pharmaceutical composition for reducing cancer cell motility.
  • an isolated peptide comprising the amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 4 or any functional fragments or derivatives of the isolated peptide in the preparation of a pharmaceutical composition for reducing cancer cell motility is disclosed.
  • Cells (human adenocarcinoma pancreatic cancer cells and human breast cancer cells) were grown in an incubator at 37°C, 5% CO 2 until reaching 70-80% density in the flask. Upon reaching 70-80% density, the cells were treated as follows: the culture medium was discarded, and the flask was washed with Trypsin EDTA (5ml, Biological industries cat no. 03-052-1B). An additional volume of 5ml Trypsin EDTA was then added to the cells and the cells were placed in the incubator for a few minutes (5-10 minutes) at 37°C, 5% CO 2 until most of the cells were detached from the flask. It is recommended to avoid tapping on the flask to increase detaching of the cells. Flasks were purchased from Nunc (cat no. 178905).
  • RPMI medium (10 ml) was then added to the Trypsin-treated cells.
  • the medium was prepared by supplementing RPMI 1640 (containing L-Glutamine and 25mM HEPES, Renium cat no. 52400) with 50 ml FBS (Biological industries cat no. 04-121-1A), 5 ml Sodium pyruvate (Biological industries cat no. 03-042-1B), 5 ml Pen-Strep (Biological industries cat no. 03-031-1B) and 5 ml Non essential amino acids (Biological industries cat no. 03-340-1B).
  • the medium and Trypsin-treated cells were then divided into 2 flasks and each flask was supplemented with additional 15 ml fresh medium. The cells were grown 2-3 days until reaching 70-80% cell density. The above procedure was then repeated.
  • GMP Good Manufacturing Practice
  • Nerofe powder was dissolved with Dimethyl sulfoxide (DMSO) such that 10 mg/ml or 20 mg/ml Nerofe solution was obtained and then further diluted with medium to obtain twice of the desired assay concentration, while not exceeding a concentration of total 2% DMSO in the final cell suspension.
  • DMSO Dimethyl sulfoxide
  • the final Nerofe concentrations used in the experiments were 1, 10, 25 and 50 ⁇ g/ml.
  • a similar amount of DMSO was added to the control cells that were not incubated in the presence of Nerofe.
  • Human adenocarcinoma pancreatic cancer cells and human breast cancer cells were grown until reaching 70-80% density in the flask and detached from the flask using Trypsin EDTA as described above (the above protocol for cell culturing was used until the step of adding 10 ml medium to the Trypsin-treated cells).
  • the cells suspended in medium and Trypsin were then transferred into a 50 ml conical tube and centrifuged at 300g (10 min, 4°C). The supernatant was then discarded and the cell pellet was re-suspended in fresh medium (2 ml medium prepared as described above).
  • the cells were then fluidized and additional 3 ml medium were added to the cell suspension such that the cells were re-suspended in a total volume of 5 ml medium.
  • the cells were then counted and diluted to a concentration of 20,000 cells/ml medium.
  • the cells were placed in a 96 well plate (Nunc cat no. 167008), placing 100 ⁇ l cell suspension per well, such that each well contained 2000 cells.
  • the cells were then incubated over-night in 37°C in the incubator.
  • the concentrated Nerofe peptide was suspended in a total volume of 100 ⁇ l medium and added to the assayed cells in the 96-well plate to a final concentration of 1, 10, 25 and 50 ⁇ g/ml.
  • Control (background) assays were performed in the absence of the peptide, namely, 100 ⁇ l medium was added to control cells.
  • the cells were incubated in the presence of the Nerofe peptide for 24 or 48 hours in 37°C. Then 20 ⁇ l per well of bromodeoxyuridine (BrdU) reagent (Millipore cat no. 2752, diluted 1:500 in medium) was added to the wells, 24 hours before cells were harvested. Namely, BrdU was added either immediately upon incubation with the peptide or after the first 24 hours of incubation in experiments in which the cells were incubated for 48 hours.
  • the BrdU kit (Cell Signaling Ltd) was used according to the manufacturer's protocol.
  • Human adenocarcinoma pancreatic cancer cells were grown until reaching 70-80% density in the flask and were detached from the flask using Trypsin EDTA as described above. Cells suspended in medium and Trypsin were then centrifuged and re-suspended in 2 ml fresh medium (as described for the BrdU incorporation assay, above).
  • the cells were then fluidized and 3 ml medium were added to the cell suspension such that the cells were re-suspended in a total volume of 5 ml medium. Cells were counted and diluted to a concentration of 50,000 cells/ml medium. Next, the cells were placed in each well of a 6 well plate (Nunc cat no. 140675), by placing 2 ml cells culture per well such that each well contains 100,000 cells. The cells were next incubated over-night at 37°C in the incubator.
  • the supernatant was discarded and replaced by 1 ml RPMI medium containing 2.5% FBS. Cells were then incubated for 24 hours or 48 hours at 37°C in the presence of the Nerofe peptide at the final concentrations of 1, 10, 25 and 50 ⁇ g/ml. The supernatant was collected by centrifugation of the cells (5 minutes at 300g, 4°C) and stored at -20°C.
  • TPA ELISA assay was performed as follows: the supernatant was thawed and kept on ice, then diluted 1:15 with the TPA diluents provided with the kit (x1N, Abcam cat no. ab108914). The procedure was continued according to the manufacturer's protocol and ELISA plates were read at an optical density (O.D.) of 450/590.
  • Human adenocarcinoma pancreatic cancer cells and human breast cancer cells were grown until reaching 70-80% cell density in the flask and were detached from the flask using Trypsin EDTA as described above. Cells suspended in medium and Trypsin were then centrifuged and re-suspended in 2 ml fresh medium (as described for the BrdU incorporation assay above).
  • the cells were then fluidized and 3 ml medium were added to the cell suspension such that the cells were re-suspended in a total volume of 5 ml medium. The cells were then counted and diluted to a concentration of 50,000 cells/ml medium. Cells at 2 ml per plate were placed in each well of a 6 well plate such that each well contained 100,000 cells. The cells were incubated over-night in 37°C in the incubator.
  • the supernatant was discarded and replaced by 1 ml RPMI medium containing 2.5% FBS.
  • the cells were then incubated for 24 or 48 hours in 37°C in the presence of the Nerofe peptide at the final concentrations of 1, 10, 25 and 50 ⁇ g/ml.
  • the supernatant was collected by centrifugation of the cells (5 minutes, 300g, 4°C) and stored at -20°C.
  • a sST2 ELISA assay was performed as follows: first, a calibration curve was prepared for the sST2 peptide by serial dilutions of sST2 peptide (Genmed, project ID 35622 B-Form, sequence: HTVRLSRKNPSKECF) in PBS (Biological industries, 02-023-5A) from 10,000 pg/ml to 156 pg/ml. Then the supernatant samples were thawed and keep on ice (concentrated samples were diluted in PBS). Sample loading was performed by loading 100 ⁇ l duplicates of each sample and of the standard in a Maxisorp 96-wells plate (NUNC, F96 Maxisorp, 442404). The loaded plates were incubated at 4°C overnight with gentle orbital shaking.
  • Samples were then washed by removing the liquid and washing the plate 3 times using a multi-pipette or an automated washer with 300 ⁇ l 0.05% TW-20 (Amresco, 0777-1L) in PBS. Samples were blocked by diluting 5% BSA (MP biomedicals, 160069) in PBS and loading 300 ⁇ l of the blocking buffer in each well. The blocking step included an incubation period of 1 hour with shaking (350 RPM) at room temperature (RT). Next, the samples were washed as described above.
  • BSA MP biomedicals, 160069
  • Detecting of sST2 was performed by diluted anti-sST2 Affinity purified antibody (Genmed, project ID 35622 B-Form) 1:100 in diluent (0.05% TW-20, 0.1% BSA in PBS), where 100 ⁇ l of the detection antibody was loaded on each well. Samples were then incubated 1.5 hours at R.T. with shaking (350 RPM) and washed as described above. Diluted (1:500 in diluent) goat anti-rabbit HRP conjugate antibody (Cell signaling, 7074) was then loaded on each well (100 ⁇ l) and the samples were further incubated 30 minutes at R.T. with shaking.
  • Human adenocarcinoma pancreatic cancer cells were grown until reaching 70-80% cell density in the flask and detached from the flask using Trypsin EDTA as described above. Cells suspended in medium and Trypsin were then centrifuged 10 minutes at 300g (4°C) and re-suspended in 2 ml fresh medium (as described for the BrdU incorporation assay above).
  • the cells were then fluidized and 3 ml medium were added such that the cells were suspended in a volume of 5 ml medium and subsequently counted and diluted to a concentration of 150,000 or 300,000 cells/ml medium.
  • Dulbecco's modification of Eagle's medium (DMEM, Biological Industries cat no. 01-055-1A) supplemented with 50 ml FBS (Biological industries cat no. 04-121-1A), 5 ml Hepes 1M (Biological industries cat no. 03-025-1C), 0.5 ml Amphotericin B 2500 ⁇ g/ml (Biological industqries cat no. 03-029-1) and 5 ml Gentamycin sulfate 50mg/ml (Biological industries cat no. 03-035-1) was used for cell culturing and re-suspension and the cells were re-suspended to a final concentration of 100,000 cells/ml medium.
  • DMEM Dulbecco's modification of Eagle's medium
  • FBS Biological industries cat no. 04-121-1A
  • Hepes 1M Biological industries cat no. 03-025-1C
  • Amphotericin B 2500 ⁇ g/ml Biological industqries cat
  • a radius 96-well Cell Migration Assay plate (Cell Biolabs Inc. cat no. CBA-126) was prepared according to the manufacturer's protocol and each well was loaded with 100 ⁇ l cells such that each well contained 10,000, 15,000 or 30,000 cells. The cells were incubated overnight at the incubator (37°C). Next, the supernatant was discarded and replaced by 100 ⁇ l RPMI containing 2.5% FBS. Cells were then treated by the Nerofe peptide suspended in a total volume of 100 ⁇ l medium (at the final concentrations of 1 and 10 ⁇ g/ml), such that each well contained a total volume of 200 ⁇ l. The cells were then incubated at 37°C for 24 hours in an incubator.
  • the supernatant was discarded and replaced by 200 ⁇ l DMEM containing 2.5% FBS and the required treatment, namely control (without Nerofe), 10, 25 or 50 ⁇ g/ml Nerofe.
  • the cells were then incubated at 37°C for 48 hours in an incubator.
  • the supernatant was discarded and the gel was removed from the center of the well, without affecting the attachment of cells as described in the manufacturer's protocol. Then, the area that was free of cells was photographed, using an inverted confocal microscope (at a magnification of x40) at zero time (i.e. right after the gel was removed) and then every two hours. The assay was concluded by staining the cells according to manufacturer's protocol.
  • TPA tissue plasminogen activator
  • FIG. 1 shows human adenocarcinoma pancreatic cancer cells that were incubated in the presence of 1-50 ⁇ g/ml of the Nerofe peptide for 24 hours and then assessed for the levels of TPA by an ELISA assay, as described above.
  • TPA pancreatic cancer cells
  • the T1/ST2 receptor (also referred to as Interleukin 1 receptor-like 1) is a member of the Toll-like receptor superfamily. Both soluble and membrane-bound T1/ST2 receptors are predominantly expressed in hematopoietic tissues in vivo (8). It has been recently reported that the knockdown of the soluble form of ST2 (sST2), decreased ErbB2-induced cell motility in various cell lines (9).
  • T101 peptide as indicated in Table 1 above, having the amino acid sequence denoted by SEQ ID NO. 2, was previously demonstrated by the inventors to significantly reduce tumor size in adult Balb/C mice model (3).
  • Nerofe peptide which is a modified peptide fragment of the T101 peptide, consisting of the C-terminal 14 amino acid residues thereof as all D amino acid residues (denoted by SEQ ID NO. 4) was previously shown to inhibit cell proliferation in various cancer cells of hematopoietic origin.
  • An "inhibitory effect on cell proliferation” is herein defined as at least 40% inhibition of cell proliferation in the presence of the peptide compared to a control assay conducted in the absence of the peptide.
  • the effect of the Nerofe peptide on cell migration was directly assayed using the Radius Cell Migration Assay, according to the manufacturer's protocol. Briefly, the cells were seeded in the well of a Radius 96-well plate (Cell Biolabs Inc. cat no. CBA-126) and adhered everywhere except in the center of the well where a biocompatible hydrogel spot was placed. Once cells formed a monolayer, the assay was initiated by gently dissolving the gel with a removal solution, leaving a gap across which cell migration can occur.
  • the effect of the Nerofe peptide on the migratory ability of human adenocarcinoma pancreatic cancer cells was further assayed under different assay conditions, namely by subjecting the cells to an incubation period of 48 hours prior to initiating the assay, in the presence of 0, 10, 25 and 50 ⁇ g/ml Nerofe peptide.
  • FIG. 4 shows results obtained in two independent migration assays performed with human adenocarcinoma pancreatic cancer cells that were incubated in the presence of 25 ⁇ g/ml Nerofe peptide (T1 and T2) for 48 hours prior to initiating the migration assay and results obtained in four independent assays performed with control cells (CON1, CON2, CON3 and CON4).
  • VEGF Vascular endothelial growth factor
  • Serum levels of VEGF were measured in blood samples obtained form these patients using an Elisa kit for human VEFG (R&D systems) and the results are presented in Figure 5 (for the patients of Cohort 1 and Cohort 2) and in Figure 6 (for the patients of Cohort 3 and Cohort 4).
  • metastasis and tumor cells migratation occur through blood vessels, upon decreasing the levels of VEGF, blood vessels are less permeable and metastasis may be inhibited.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP14824545.9A 2013-12-05 2014-12-04 Pharmaceutical compositions and methods for the treatment and prevention of metastatic cancer Active EP3076988B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361912156P 2013-12-05 2013-12-05
PCT/IL2014/051058 WO2015083167A1 (en) 2013-12-05 2014-12-04 Pharmaceutical compositions and methods for the treatment and prevention of metastatic cancer

Publications (2)

Publication Number Publication Date
EP3076988A1 EP3076988A1 (en) 2016-10-12
EP3076988B1 true EP3076988B1 (en) 2019-06-05

Family

ID=52292983

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14824545.9A Active EP3076988B1 (en) 2013-12-05 2014-12-04 Pharmaceutical compositions and methods for the treatment and prevention of metastatic cancer

Country Status (11)

Country Link
US (1) US9878015B2 (zh)
EP (1) EP3076988B1 (zh)
JP (1) JP6609556B2 (zh)
KR (1) KR102384795B1 (zh)
CN (1) CN105939724B (zh)
AU (1) AU2014358671B2 (zh)
CA (1) CA2931023C (zh)
DK (1) DK3076988T3 (zh)
ES (1) ES2742856T3 (zh)
IL (1) IL245998B (zh)
WO (1) WO2015083167A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116688096A (zh) * 2016-02-04 2023-09-05 免疫系统密钥有限公司 在癌症疗法作为预测工具的内质网应激和用于癌症治疗的联合疗法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1809660B1 (en) * 2004-10-25 2014-07-23 Immune System Key Ltd. A thymus-specific protein
WO2007091240A2 (en) 2006-02-06 2007-08-16 Immune System Key Ltd. Treatment of immunological diseases
WO2007122622A1 (en) * 2006-04-24 2007-11-01 Immune System Key Ltd. Method of treatment of a disease
US20100204097A1 (en) 2006-12-18 2010-08-12 Immune System Key Ltd. Therapeutic methods using a thymus peptide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
AU2014358671B2 (en) 2019-09-12
AU2014358671A1 (en) 2016-06-02
CN105939724B (zh) 2020-01-14
US9878015B2 (en) 2018-01-30
KR20160085361A (ko) 2016-07-15
IL245998B (en) 2019-12-31
KR102384795B1 (ko) 2022-04-08
US20160303200A1 (en) 2016-10-20
ES2742856T3 (es) 2020-02-17
DK3076988T3 (da) 2019-09-16
CA2931023A1 (en) 2015-06-11
JP6609556B2 (ja) 2019-11-20
IL245998A0 (en) 2016-07-31
CA2931023C (en) 2023-12-19
JP2017505755A (ja) 2017-02-23
EP3076988A1 (en) 2016-10-12
WO2015083167A1 (en) 2015-06-11
CN105939724A (zh) 2016-09-14

Similar Documents

Publication Publication Date Title
JP6748155B2 (ja) 線維症抑制活性を有するペプチド及びこれを含む組成物
UA123392C2 (uk) Пептид, здатний зв'язуватися з молекулою головного комплексу гістосумісності (mhc) людини i класу, та його застосування для лікування раку
US10034922B2 (en) Peptide having angiogenesis inhibitory activity and composition containing same
UA124577C2 (uk) Пептид для лікування раку
KR20200100866A (ko) 항-전이성 요법에서 ａｘｌ 신호전달의 저해
JP6104872B2 (ja) 細胞取込を最適化するための抗分泌性因子（ａｆ）の使用
US20240108686A1 (en) DPEP-1 Binding Compositions and Methods of Use
EP2266593A1 (en) Use of CD44v6 in the treatment of ophthalmic diseases
US20220048973A1 (en) B1SP Fusion Protein Therapeutics, Methods, and Uses
US9789213B2 (en) EGFL7 targeting and/or binding polypeptides and methods for inhibiting angiogenesis
EP3076988B1 (en) Pharmaceutical compositions and methods for the treatment and prevention of metastatic cancer
KR20230120585A (ko) c-MET의 에피토프 및 HIF1α의 에피토프를 포함하는 암 백신 및 이의 용도
KR20230120542A (ko) c-MET의 에피토프 및 HIF1α의 에피토프를 포함하는 암 백신 및 이의 용도
JP2016501856A (ja) 乳癌を処置するためのｃｄ４４ｖ６由来ペプチド
TW201545754A (zh) 用於抑制骨髓衍生抑制細胞之組成物

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20160629

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20170622

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1229242

Country of ref document: HK

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20190122

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1139309

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190615

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602014047950

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: SERVOPATENT GMBH, CH

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20190912

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190905

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190605

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190605

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190605

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190605

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190905

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190906

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190605

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1139309

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190605

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190605

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190605

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190605

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190605

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191007

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2742856

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20200217

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191005

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190605

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602014047950

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190605

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190605

26N No opposition filed

Effective date: 20200306

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190605

REG Reference to a national code

Ref country code: CH

Ref legal event code: PCAR

Free format text: NEW ADDRESS: WANNERSTRASSE 9/1, 8045 ZUERICH (CH)

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20141204

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190605

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230714

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20231013

Year of fee payment: 10

Ref country code: FR

Payment date: 20230929

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20231012

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20231002

Year of fee payment: 10

Ref country code: IT

Payment date: 20231110

Year of fee payment: 10

Ref country code: IE

Payment date: 20231009

Year of fee payment: 10

Ref country code: DK

Payment date: 20231214

Year of fee payment: 10

Ref country code: DE

Payment date: 20231010

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20231121

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240115

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20240101

Year of fee payment: 10